Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
LRP2 is a potential molecular target for nonsyndromic pathological myopia
Kimberley Delaunay, … , Olivier Cases, Francine Behar-Cohen
Kimberley Delaunay, … , Olivier Cases, Francine Behar-Cohen
Published June 24, 2025
Citation Information: JCI Insight. 2025;10(15):e192929. https://doi.org/10.1172/jci.insight.192929.
View: Text | PDF
Research Article Neuroscience Ophthalmology

LRP2 is a potential molecular target for nonsyndromic pathological myopia

  • Text
  • PDF
Abstract

High myopia (HM) and posterior staphyloma (PS) are major causes of vision loss worldwide. Genetic and environmental factors, especially light exposure, influence myopia. This study shows that low-density lipoprotein–related receptor type 2 (LRP2) levels are decreased in the vitreous of patients with HM and PS, and that in human donor eyes affected by PS, LRP2 expression was reduced in the neural retina and retinal pigment epithelium (RPE), with morphologic changes similar to those observed in the Foxg1-Cre-Lrp2fl/fl mouse that also develops PS. In human induced pluripotent stem cell–derived RPE cells, LRP2 silencing regulated genes involved in eye and neuronal development, visual perception, tissue remodeling, hormone metabolism, and RPE structure. Its expression increased under light exposure, particularly red light, but was downregulated by cortisol. These findings establish a link between LRP2, myopization, and environmental factors, highlighting its crucial role in nonsyndromic HM and PS. LRP2 appears to be a promising therapeutic target for HM treatment.

Authors

Kimberley Delaunay, Emilie Picard, Patricia Lassiaz, Laurent Jonet, Vidjea Cannaya, José Maria Ruiz-Moreno, Kentaro Kojima, Henrik Vorum, Bent Honoré, Jorge Ruiz-Medrano, Lasse Jørgensen Cehofski, Eric Pussard, Renata Kozyraki, Alicia Torriglia, Olivier Cases, Francine Behar-Cohen

×

Figure 4

LRP2 immunolabeling in the emmetropic and HM retina.

Options: View larger image (or click on image) Download as PowerPoint
LRP2 immunolabeling in the emmetropic and HM retina.
(A and B) In the em...
(A and B) In the emmetropic neural retina, LRP2 is expressed around RGCs and along GS-positive glial Müller cells. (C and D) In the HM neural retina, LRP2 expression is greatly reduced in GS-positive cells, which surround cysts (stars). (E) In transversal sections of RPE cells, LRP2 is located at the apical pole (white arrowheads), in intracellular vesicles, and at the basal pole of the RPE, and in the pillars of the choriocapillaris. (F and G) In an RPE flat-mounted preparation from the left emmetropic eye, LRP2 is distributed in cytoplasmic vesicles (F) along apical and lateral membranes (G) and most LRP2-positive vesicles are also positive for clathrin. (I) In transversal section of the HM RPE, LRP2 expression is greatly diminished and absent in the choriocapillaris. (J–L) In RPE flat mounted from the HM eye, LRP2 distribution is sparse and diffuse, and does not colocalize with clathrin (L) that is also diminished. Scale bars: 200 μm (A–D), 10 μm (E and I), and 50 μm (F, G, and J–L).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts